This enhancement in anti-tumor capability of CD8+ T cells was accompanied by a reduction in the incidence of adverse drug reactions, indicating that G-TMPs may enhance the efficacy and safety of FBC in treating advanced gastric cancer. The gene discussed is CD8A; the disease is gastric cancer.